OKYO Pharma has reported encouraging top-line outcomes from the randomised Phase II trial of urcosimod to treat NCP.| Clinical Trials Arena
FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.| Clinical Trials Arena
The relationship between neurodegenerative conditions and late-life mood disorders (LLMDs) is largely unexplored.| Clinical Trials Arena
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as potential treatments for a broader range of chronic conditions, including metabolic dysfunction-associated steatohepatitis and Alzheimer’s disease.| Clinical Trials Arena